Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model

PurposeThe selective androgen receptor modulator ostarine has been shown to have advantageous effects on skeletal tissue properties, reducing muscle wasting and improving physical function in males. However, data on effects in male osteoporosis remain limited. In this study, the effects of ostarine on osteoporotic bone were evaluated in a rat model of male osteoporosis and compared with those of testosterone treatments.MethodsEight-month-old male Sprague-Dawley rats were either non-orchiectomized to serve as a healthy control (Non-Orx, Group 1) or orchiectomized (Orx, Groups 2-6) and then grouped (n = 15/group): (1) Non-Orx, (2) Orx, (3) Ostarine Therapy, (4) Testosterone Therapy, (5) Ostarine Prophylaxis and (6) Testosterone Prophylaxis. Prophylaxis treatments started directly after orchiectomy and continued for 18 weeks, whereas Therapy treatments were initiated 12 weeks after Orx. Ostarine and Testosterone were applied orally at daily doses of 0.4 and 50 mg/kg body weight, respectively. The lumbar vertebral bodies and femora were analyzed using biomechanical, micro-CT, ashing, and gene expression analyses.ResultsOstarine Prophylaxis showed positive effects in preventing osteoporotic changes in cortical and trabecular bone (femoral trabecular density: 26.01 & PLUSMN; 9.1% vs. 20.75 & PLUSMN; 1.2% in Orx and in L4: 16.3 & PLUSMN; 7.3% vs 11.8 & PLUSMN; 2.9% in Orx); biomechanical parameters were not affected; prostate weight was increased (0.62 & PLUSMN; 0.13 g vs 0.18 & PLUSMN; 0.07 g in Orx). Ostarine Therapy increased solely the cortical density of the femur (1.25 & PLUSMN; 0.03 g/cm(3) vs. 1.18 & PLUSMN; 0.04 g/cm(3) in Orx); other bone parameters remained unaffected. Testosteron Prophylaxis positively influenced cortical density in femur (1.24 & PLUSMN; 0.05 g/cm(3) vs. 1.18 & PLUSMN; 0.04 g/cm(3) in Orx); Test. Therapy did not change any bony parameters.ConclusionOstarine Prophylaxis could be further investigated as a preventative treatment for male osteoporosis, but an androgenic effect on the prostate should be taken into consideration, and combination therapies with other anti-osteoporosis agents could be considered.